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Computerized Digital Dermoscopy: SensitivityAnd Speci¢city
Aren’t Enough
To the Editor:
The proliferation of new diagnostic technology requires that der-
matologists become familiar with test characteristics, such as sen-
sitivity, speci¢city, positive predictive value, and false negativity,
when caring for patients. A recent article by Rubegni et al (2002)
investigating computerized melanoma digital dermoscopy exem-
pli¢es the increasing value of these test characteristics in the der-
matology literature. In this study, the authors report a sensitivity
of 93% and a speci¢city of 92.75% for their diagnostic test, and
suggest that it is superior to other forms of dermoscopy. We
would like to take the opportunity to demonstrate how clinicians
can apply these test characteristics to evaluate the usefulness of
this new technology for their patient population.
Although sensitivity and speci¢city are informative measures
of test performance, they cannot inform clinicians of the prob-
ability that an individual patient has melanoma. This limitation
results from the fact that these test characteristics are determined
from patient groups known a priori to have or to not have
the disease (Giard and Hermans, 1996). Sensitivity refers to the
probability of a positive test result in a person who has the
disease. Speci¢city refers to the probability of a negative test
in a person who does not have the disease.When seeking a diag-
nosis, clinicians do not know their patients’ true disease state.
Thus, the property of interest to clinicians is not the test’s sensi-
tivity or speci¢city, but its predictive value: the probability that
a patient has the disease given a positive test result, or, alterna-
tively, the probability that a patient does not have the disease gi-
ven a negative test result. These concepts refer to a test’s positive
predictive value (PPV) and negative predictive value (NPV),
respectively. The PPV may be calculated using Bayes’ theorem,
which combines three estimates: (1) test sensitivity; (2) test speci-
¢city; and (3) the patient’s pre-test probability (Smith et al, 2000).
The negative predictive value may be calculated similarly,
but is described elsewhere (Hagen, 1995) Under Bayes’ theorem,
PPV is the fraction of the patients who truly have the disease
among all patients with a positive test result (Smith et al, 2000)
Mathematically, this expression is
PPV ¼
pre-testprobabilitysensitivity
½pre-testprobabilitysensitivity
þ ½ð1-pre-testprobabilityÞð1-specificityÞ
Pre-test probability refers to the probability that the patient
under investigation has the disease of interest. In the case of mel-
anoma, pre-test probability may be estimated using history (i.e.,
family history of melanoma, number of blistering sunburns in
youth), physical examination (i.e., lesion morphology, number
of nevi, skin phototype), as well as knowledge of the approximate
prevalence of melanoma in the population being tested. An Afri-
can-American child with no signi¢cant historical or physical
¢ndings other than a clinically atypical pigmented lesion on the
palm, for example, may have a pre-test probability of 0.01 for
melanoma. By contrast, a 68 y old Caucasian man with a previous
history of melanoma and a clinically atypical and changing pig-
mented lesion on the back may have a pre-test probability of 0.60
for a new melanoma. Because even an excellent test, as de¢ned
by its sensitivity and speci¢city, may have poor predictive value
when used in patients with a low pre-test probability, clinicians
must consider a patient’s pre-test probability when assessing the
clinical relevance of new diagnostic technology (Grimes and
Schultz, 2002).
Another test measure of interest to clinicians is the probability
that a patient has the disease of interest given a negative test re-
sult, that is, the probability of a false negative result. As NPV cap-
tures the probability that a patient does not have the disease given
a negative test result (i.e., the probability of a true negative result),
the probability of a false negative result is the complement of
NPV, that is, 1-NPV.
Applying the reported sensitivity (93%) and speci¢city
(92.75%) of Rubegni et al’s test to Bayes’ theorem, we determined
the PPV and 1-NPV for a range of clinically reasonable pre-test
probabilities: 0.01 (a very low-risk melanoma patient) to 0.95 (a
very high-risk melanoma patient) by increments of 0.05 using
SAS statistical software. Results are presented in Table I. Based
on its PPV, Rubegni et al’s test appears to be a powerful diagnostic
aid. A positive test result increases the probability that a particular
patient may have melanoma even for patients with very low pre-
test probabilities (for a patient with pre-test probability of 0.01, it
yields a 10-fold increase for a PPV of 0.11). It is further associated
with an acceptable 1-NPV, or false negative probability (given a
negative test result, a patient with a 0.15 pre-test probability for
melanoma only has a 0.01 probability of having the disease).
These results are clinically important because some dermatolo-
gists may opt to observe a lesion with only a 1% probability of
being melanoma, whereas a lesion with 410% probability of
being melanoma would receive more aggressive management.
Tests with PPV and 1-NPV that change patient management are
thus clinically important.
Even with good PPV and 1-NPV, however, new diagnostic
technology may still not be practical, particularly in settings
where the clinician has a very low threshold to act upon a suspi-
cion. In the case of melanoma, clinicians confront a disease that is
eminently and easily curable in its early stages, but associated
with a high degree of therapy-related morbidity and almost uni-
versal fatality in its advanced stages. Melanoma thus represents a
lesion for which the biopsy threshold for most dermatologists is
quite low. As biopsy would obviate the need for digital dermo-
scopy, it is crucial for clinicians to ask under which pre-test
probabilities would digital dermoscopy alter their decision
and bene¢t their patient. Given the severity of melanoma, it
may be reasonable to assume that many dermatologists would
biopsy pigmented lesions with a pre-test probability for melano-
ma X0.01 (1 in 100 chance, or greater), and may observe those
with a lesser pre-test probability. If this assumption is accurate, a
positive test result using digital dermoscopy would be clinically
informative solely in the subset of patients with a pre-test prob-
ability less than 0.01, as the remainder of patients would receive a
biopsy irrespective of the test result (Table I). Similarly, a nega-
tive test result would be meaningful solely in the subset of pa-
tients with pre-test probabilities less than 0.05, as the probability
for a false negative becomes unacceptably high once pre-test
probabilityX0.10 (Table I). Rubegni et al’s test may only be use-
ful in low-risk pigmented lesions (pre-test probability: 0.01^0.05).
Further, if the clinician’s patient population has a very low preva-
lence of melanoma, the digital dermoscopy will not be put to use
often.
Particular clinical scenarios, however, may warrant use of digi-
tal dermoscopy. For example, a clinician may be hesitant to
biopsy a pigmented lesion located at the lateral canthus of a 7 y
old child if this lesion is associated with a low pre-test probability
(for instance, 0.05). Use of Rubegni et al’s test in this context may
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increase the PPV to 0.59 if the result is positive, or yield an accep-
table 1-NPV of 0.004 if the test is negative, and thus provides
important information to the clinician attempting to make a dif-
¢cult decision. Selective use in settings where the decision to
biopsy may result in an adverse patient outcome may be a poten-
tial use for computerized digital dermoscopy.
When assessing the clinical relevance of diagnostic technology,
clinicians must consider a test’s PPV and 1-NPV (not just its sen-
sitivity and speci¢city) and the pre-test probabilities where its use
may inform clinical decisions. Whereas Rubegni et al’s tool ap-
pears to be a powerful diagnostic aid, whether the additional
amount of clinical information the tool provides justi¢es the cost
of technology requires us to consider the broad determinants of
medical decision-making: physician behavior, disease prevalence,
outcome, cost, and values.
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Active Human Herpesvirus 6 Infection in a Patient with Drug
Rash with Eosinophilia and Systemic Symptoms
To the Editor:
Clinical and biologic manifestations of drug rash with eosinophi-
lia and systemic symptoms (DRESS) are well characterized and
mimic viral infection: high fever, facial edema, erythroderma fol-
lowed by an exfoliative dermatitis, di¡use lymphadenopathy, hy-
pereosinophilia, atypical circulating lymphocytes, abnormal
results of liver function tests. Other systemic manifestations may
occur (e.g., pneumonitis, pancreatitis, neurologic symptoms).
This drug adverse reaction was ¢rst described with anticonvulsi-
vants but minocycline is also well known to induce this kind of
reaction (Disdier et al, 2001).
The role of viral infection in the development of this drug
adverse reaction is suspected. We implicated for the ¢rst time
human herpesvirus 6 (HHV-6) infection in a patient with pheno-
barbital-induced DRESS complicated by a fulminant hemopha-
gocytic syndrome (Descamps et al, 1997). In a small prospective
series of seven consecutive patients hospitalized with DRESS
we demonstrated serologic evidence of HHV6 active infection
(Descamps et al, 2001). But evidence of viremia, which is the
main criterion for con¢rmation of active infection, was not de-
monstrated in these cases (Descamps and Mahe, 2002; Tohyama
and Hashimoto, 2002). Recently, we and others reported HHV-
6 encephalitis associated with DRESS (Descamps et al, 2003).We
report here a typical case of DRESS associated with minocycline
and bring evidence of viremia by quanti¢cation of HHV-6 DNA
in serum samples.
A black 25-y-old patient was prescribed minocycline for the
treatment of folliculitis on the scalp on the 16 May 2000. Seven
weeks later on the 7 July 2000 he developed an erythroderma and
Table I. Bayes’ theorem output: relation between pre-test
probability, PPV, and 1-NPV for a new melanoma digital
dermoscopic analysis
Pre-test probability PPV 1-NPV
0.01 0.11 0.0008
0.05 0.40 0.004
0.10 0.59 0.01
0.15 0.69 0.01
0.20 0.76 0.02
0.25 0.81 0.02
0.30 0.85 0.03
0.35 0.87 0.04
0.40 0.90 0.05
0.45 0.91 0.06
0.50 0.93 0.07
0.55 0.94 0.08
0.60 0.95 0.10
0.65 0.96 0.12
0.70 0.97 0.15
0.75 0.97 0.18
0.80 0.98 0.23
0.85 0.99 0.30
0.90 0.99 0.40
0.95 0.99 0.59
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